Compare ZJYL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | CVM |
|---|---|---|
| Founded | 2006 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 20.4M |
| IPO Year | 2020 | 1996 |
| Metric | ZJYL | CVM |
|---|---|---|
| Price | $1.93 | $1.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 335.8K |
| Earning Date | 08-20-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.10 | $0.89 |
| 52 Week High | $4.50 | $13.48 |
| Indicator | ZJYL | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 52.26 |
| Support Level | $0.16 | $0.95 |
| Resistance Level | $2.59 | $1.46 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 14.06 | 52.78 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.